Navigation Links
Hypogonadism in Medical News

New recommendations by scientific societies about late-onset hypogonadism

Arnhem, 04 December 2008 The January issue of European Urology , the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations. LOH is a clinical and bioc...

QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options

... Although testosterone levels decline with age, hypogonadism is not a natural consequence of the aging process. "Men with clinically diagnosed hypogonadism do not need to 'tolerate' the symptoms of low test...countries by Bayer Schering Pharma AG. ABOUT hypogonadism Hypogonadism, also known as low testosterone...

Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show

...ased new long-term clinical trial data in men with hypogonadism who were treated for 21 months with testosterone u...rology at Harvard Medical School . "But treating hypogonadism can result in significant health benefits for pati.... Morgentaler noted: "Because men who suffer from hypogonadism need to remain on treatment for life, it is very i...

Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer

... 2004, Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals where he participated in an ANDA for testosterone gel for the treatment of hypogonadism that was approved 2005. He also participated in multiple INDs in oncology and autoimmune diseases leading to successful phase I and phase II programs...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

...tly markets products to treat overactive bladder, prostate cancer and central precocious puberty and is pursuing regulatory approval of drugs to treat hypogonadism and bladder cancer. Mr. Holveck noted, "In addition to the very successful drug, VANTAS(R), we are particularly excited about the opportunity to ...

JCI online early table of contents: July 1, 2008

...d and colleagues, at Massachusetts General Hospital, Boston, has identified mutations in the FGF8 gene in individuals with idiopathic hypogonadotropic hypogonadism (IHH), a disease characterized by failed sexual maturation and infertility due to a deficiency in the small protein gonadotropin-releasing hormone (Gn...

FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus

...ights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...

Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men

... Prolonged hypogonadism may result in erectile dysfunction, decreased libido, anemia, sarcopenia, m...ne level is well-known for its association with osteoporosis, the impact of hypogonadism on overall physical functioning and fall risk has not been prospectively ev...

Detrimental Effect Of Chronic Alcoholism On Male Fertility

...ht cause gonadal disorders, including structural testicular changes and a decrease in testicular and serum levels of T, which might be involved in the hypogonadism and feminization phenotype. A reduction in sperm concentration and in the percentage of spermatozoa with normal morphology has been detected in ch...
Hypogonadism in Medical Technology

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal(TM), an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonst...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

...preclinical program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Be...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...tners in Europe and other territories. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ch...icantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile dysfunct...

QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (beco...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

...aged 40-69 years, it is estimated that there are about 481,000 new cases of hypogonadism per year. Overall, approximately 2.4 million U.S. men suffer from the condition.(1) hypogonadism results from a deficiency in testosterone secretion that may occur naturall...

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (beco...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

...ts, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial collagenas...

QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy

...cal program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) (beco...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

...been previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated ...Bayer Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...
Hypogonadism in Medical Definition

Pathology

...- Adrenal insufficiency ( Addison's disease ) - Hypoaldosteronism Gonads Polycystic ovary syndrome - 5-alpha-reductase deficiency - hypogonadism - Delayed puberty - Precocious puberty Other Autoimmune polyendocrine syndrome - Carcinoid syndrome - Laron syndrome - Psychogenic...
Hypogonadism in Medical Dictionary

Hypogonadism

Hypogonadism is a medical term for a defect of the reproductive system that results in lack of function of the gonads . The gonads have two functions: to produce hormones, activin and to produce gametes (eggs or sperm). Deficiency of sex hormones can result in defective... Male hypogonadism ...

Uremia

...ia affecting many systems of the body, ... ... like renal failure resulting in uremia in males is associated with decreased ... The cause of hypogonadism in uremia is probably multifactorial. ... ...
Hypogonadism in Biological News

Study identifies pathway required for normal reproductive development

... of Medicine. The current study is the latest in a series of investigations by the MGH group into the genetic basis of idiopathic hypogonadotropic hypogonadism (IHH), a rare condition in which puberty does not take place naturally. IHH occurs when a structure in the brain called the hypothalamus fails to dev...

New licensing agreement to maximize AIDS drug development

...ngapore and South Korea. FortigelTM (testosterone gel), branded Tostrex® outside the United States, is marketed in Sweden for the treatment of male hypogonadism also by ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of the European Union are being sought through the Mutual Recogni...
Hypogonadism in Biological Technology

QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference

...nt programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. Aso...
Hypogonadism in Biological Definition

Infertility

...oblems, i.e. diabetes mellitus , thyroid disorders Hypothalamic disorders, i.e. Kallmann syndrome Hyperprolactinemia Hypopituitarism hypogonadism due to various causes Psychological factors Drugs, alcohol Testicular factors Genetic causes, e.g. Klinefelter syndrome Neoplasm, e.g....
Other Tags
(Date:8/29/2015)... ... 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of ... will present an educational program titled “Asbestos and Your Health.” , The two and ... open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible ... lives of patients, according to a newly published report. Surviving Mesothelioma has more ... article. , The authors of the new paper focus on several types ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed results. ... improve treatment outcomes. This localized treatment seems to address the symptoms and ...
(Date:8/28/2015)... ... , ... Rio Salado College joined nine educational institutions in Washington ... the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
Other Contents